Statins are a class of drugs that lower the cholesterol level in the blood by blocking hydroxy-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) in the liver (Figure 1 ). Statins have become the most frequently prescribed agent for the treatment of hypercholesterolemia due to their effect on reducing the rates of cardiovascular events.
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1 Fluvastatin (Lescol TM ) inhibits the enzyme that reduces 3-hydroxy-3-methylglutaric acid to mevalonic acid, thus blocking cholesterol biosynthesis and lowers low-density lipoprotein cholesterol levels by 20-30% at a daily dose of 20-40 mg. 2 It has also been shown to exhibit antiviral activity against Hepatitis C.
3
Due to their potent pharmacological effects and the unique structural features, statins have attracted considerable attention as powerful synthetic targets. The majority of synthetic approaches have focused on efficient construction of the statins side chain. 4 In 1997, the Novartis research group described a practical asymmetric synthesis of fluvastatin via a highly selective reduction of optically pure δ-hydroxyl-β-ketoesters with a subsequent Horner-Wadsworth-Emmons reaction. 5 In addition, they developed a manufacturing process for the production of fluvastatin in racemic form. 6 Recently, Hayashi and coworkers reported enantioselective total synthesis of (+)-and (-)-fluvastatin and their analogues through the reaction of an aldehyde with diketene in the presence of Ti(O i Pr) 4 and a chiral Schiff base ligand as the key step.
7
In this paper, we present a new strategy for the asymmetric total synthesis of (+)-fluvastatin analogue, that includes catalytic carbon-carbon bond formations, such as Cu-catalyzed C-3 arylation, Ir-catalyzed asymmetric allylation and Ru-catalyzed intermolecular metathesis, and diastereoselective addition for the preparation of 1,3-syn-diol.
We first investigated the direct catalytic C-3 arylation of indoles according to the reported literatures. 8 The iridium catalyzed C-3 arylation of heteroarenes with iodoarenes reported by Itami et al. 8a and the palladium catalyzed C-3 arylation of indoles with bromoarenes reported by Bellina and Rossi 8b were less effective or ineffective for our system, which is based on the coupling of indole or N-isopropyl indole and fluoroiodobenzene. However, Cu(II)-catalyzed site-selective arylation of indole (1) reported by Gaunt et al.
8c afforded our desirable C-3 arylation product 2 in high yield (70%) with a high regioselectivity (C 3 :C 2 = 10:1), as shown in Scheme 1. However, in the case of N-isopropyl indole, the reaction provided C-3 arylated product in low yield (45%) under the identical reaction conditions. Therefore, indole (1) was selected as the starting material for the total synthesis of (+)-fluvastatin analogue. The treatment of free (NH)-indole 2 with sodium hydride and isopropyl bromide in DMF furnished compound 3, which was subjected to a Vilsmeier-Haack type reaction condition using POCl 3 and 3-(N-methyl-N-phenylamino)acrolein (MPAA) in refluxing acetonitrile to give the enal 4 in 82% yield. Next, we examined the enantioselective iridium-catalyzed carbonyl allylation, described by Krische and coworkers, To prepare the 1,3-syn-diol moiety of (+)-fluvastatin, we planned to utilize the base-catalyzed intramolecular conjugate addition methodology reported by Evans et al. (Scheme 2).
11 With this efficient route to (+)-fluvastatin, our attention was then focused on the synthesis of α,β-unsaturated esters 6a-6d via olefin metathesis using ruthenium catalysts such as a first generation Grubbs catalyst, a second generation Grubbs catalyst, and a Hoveyda-Grubbs catalyst.
12 The best result was obtained when compound 5 was treated with a second generation Grubbs catalyst (1,3-bis(mesityl)-2-imidazolidinylidene substituted ruthenium) in toluene at room temperature, which provided the corresponding products 6a- Table 2 , we first attempted to couple the α,β-unsaturated methyl ester 6a and benzaldehyde via basecatalyzed intramolecular conjugate addition of a hemiacetalderived alkoxide nucleophile described by Evans.
11 However, these attempts were unsuccessful under standard reaction conditions (50 mol % KO t Bu, 550 mol % PhCHO, THF, 0 o C), and led to the recovery of the starting material 6a and the production of retro-aldol adduct 4 ( Table 2 , entry 1). Extended reaction times and the use of an excess amount of reagents (100 mol % KO t Bu, 1100 mol % PhCHO) resulted in decomposition of the starting material and the increase of retro-aldol adduct 4 in 20% yield (entry 2). However, the use of the ethyl ester 6b with 100 mol % KO t Bu and 1100 mol % PhCHO afforded the desirable product 7b (24%), the recovered starting compound 6b (40%) and the retro-aldol byproduct 4 (22%), as shown in entry 3. From these results, we screened the coupling of 6c or 6d with benzaldehyde, and obtained the corresponding products 7c (38%) and 7d (44%), respectively (entries 4 and 5). The use of KHMDS as the base was ineffective under other identical conditions (entry 6). 13 Finally, when 100 mol % of tert-butanol was used as an additive under otherwise identical conditions, homoallyl alcohol 6d was converted to the corresponding 1,3-syn-diol 7d with a high level of diastereoselectivity (15 > 1) in 52% yield.
To complete the synthesis of (+)-fluvastatin, we first investigated selective deprotection of the benzylidene acetal moiety of 7d under reported procedures, i.e., i) 80% AcOH, THF,
14 ii) BCl 3 , CH 2 Cl 2 , 15 iii) Zn(OTf) 2 , EtSH, NaHCO 3 , CH 2 Cl 2 , 16 iv) DDQ, THF, H 2 O, 17 etc. However, all reactions furnished the complicated reaction mixtures and the recovery of starting material presumably due to the instability of 3,5-dihydroxy hept-6-enoate moiety in our desired product under acidic conditions. Thus our focus moved on the synthesis of (+)-fluvastatin analogue, which contains the reduction of olefin moiety in (+)-fluvastatin (Scheme 3). After hydrogenation of olefin moiety of 7d, benzylidene acetal moiety was cleanly removed under standard acidic condition (80% AcOH, THF, 60 o C) to afford the diol 8a (23%) and the lactone 8b (44%), respectively. Finally, saponification of a mixture of the diol 8a and the lactone 8b and subsequent lyophilization provided (+)-fluvastatin analogue (9) in quantitative yield as a pale yellow powder.
In conclusion, we describe a catalytic approach to the asymmetric total synthesis of (+)-fluvastatin analogue starting from a readily available indole via Cu-catalyzed C-3 arylation, Ir-catalyzed asymmetric allylation, Ru-catalyzed intermolecular metathesis, and diastereoselective intramolecular conjugate addition of hemiacetal alkoxide anion as the key steps. This synthetic strategy can be applied to the synthesis of a broad range of statin family molecules.
